Have a feature idea you'd love to see implemented?
Let us know!
ENLV Enlivex Therapeutics Ltd
Price (delayed)
$1.14
Market cap
$23.81M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.98
Enterprise value
-$698,024
enlivex therapeutics ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. its product candidate is allocetra, an immunotherapy candidate, which is in phase iib
Highlights
Enlivex Therapeutics's EPS has increased by 33% YoY and by 17% from the previous quarter
Enlivex Therapeutics's net income has increased by 30% YoY and by 15% from the previous quarter
The company's quick ratio rose by 25% YoY but it fell by 7% QoQ
ENLV's equity is down by 31% year-on-year and by 7% since the previous quarter
Key stats
What are the main financial stats of ENLV
Market
Valuations
Earnings
Shares outstanding
20.88M
Market cap
$23.81M
Enterprise value
-$698,024
Price to earnings (P/E)
N/A
Price to book (P/B)
0.9
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$18.93M
EBIT
-$19.68M
EBITDA
-$18.97M
Free cash flow
-$14.05M
Per share
Balance sheet
Liquidity
EPS
-$0.98
EPS diluted
-$0.98
Free cash flow per share
-$0.66
Book value per share
$1.27
Revenue per share
$0
TBVPS
$1.4
Total assets
$29.8M
Total liabilities
$3.21M
Debt
$0
Equity
$26.59M
Working capital
$24.32M
Debt to equity
0
Current ratio
9.71
Quick ratio
8.78
Net debt/EBITDA
1.29
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-58.4%
Return on equity
-67.6%
Return on invested capital
-602.1%
Return on capital employed
-72.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ENLV stock price
How has the Enlivex Therapeutics stock price performed over time
Intraday
-0.87%
1 week
-8.8%
1 month
-5%
1 year
-60.28%
YTD
-2.56%
QTD
-2.56%
Financial performance
How have Enlivex Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$20.59M
Net income
-$18.93M
Gross margin
N/A
Net margin
N/A
Enlivex Therapeutics's net income has increased by 30% YoY and by 15% from the previous quarter
The company's operating income rose by 23% YoY and by 11% QoQ
Growth
What is Enlivex Therapeutics's growth rate over time
Valuation
What is Enlivex Therapeutics stock price valuation
P/E
N/A
P/B
0.9
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Enlivex Therapeutics's EPS has increased by 33% YoY and by 17% from the previous quarter
ENLV's P/B is 44% below its last 4 quarters average of 1.6 and 40% below its 5-year quarterly average of 1.5
ENLV's equity is down by 31% year-on-year and by 7% since the previous quarter
Efficiency
How efficient is Enlivex Therapeutics business performance
Enlivex Therapeutics's ROA has decreased by 22% YoY but it has increased by 3.9% from the previous quarter
Enlivex Therapeutics's ROE has decreased by 19% YoY but it has increased by 6% from the previous quarter
Dividends
What is ENLV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ENLV.
Financial health
How did Enlivex Therapeutics financials performed over time
The total liabilities has plunged by 61% YoY and by 3.9% from the previous quarter
The total assets has declined by 37% year-on-year and by 7% since the previous quarter
ENLV's debt is 100% lower than its equity
ENLV's equity is down by 31% year-on-year and by 7% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.